Immunology: Current Research
Open Access

Dendritic cells; Tumor microenvironment; Immunotherapy; Antigen presentation; Immune tolerance; Tumor progression; Tumor immunity.

Introduction

Dendritic cells (DCs) are pivotal for initiating and regulating immune responses, functioning as antigen-presenting cells that bridge innate and adaptive immunity. By capturing, processing, and presenting antigens to T cells, DCs are essential for mounting effective immune responses, particularly in the context of infections and tumors [1,2]. In the tumor microenvironment (TME), however, the functions of DCs become dysregulated, often contributing to the immune evasion mechanisms employed by tumors. Rather than stimulating an effective antitumor immune response, DCs in the TME may adopt a tolerogenic phenotype, which suppresses immune activation and promotes tumor progression [3,4]. The complexity of DC function in the TME arises from the heterogeneous nature of DCs themselves, which can take on distinct roles depending on their maturation state, receptor expression, and the cytokines present in the TME. In the presence of tumor-derived factors such as cytokines, metabolites, and exosomes, DCs can become dysfunctional or tolerogenic, which allows tumors to evade immune surveillance [5]. This shift in DC behavior is linked to the secretion of immune-suppressive cytokines like IL-10 and TGF-β, which further perpetuate tumor immune tolerance. Importantly, recent studies have revealed that DCs can be reprogrammed or targeted therapeutically to restore their immunostimulatory function, offering a promising strategy for cancer immunotherapy [6]. Several approaches are under investigation to either recruit and activate DCs in the TME or enhance their ability to present tumor-associated antigens to T cells. This approach aims to enhance the body's natural immune response to cancer and complement other immunotherapeutic strategies such as immune checkpoint inhibitors. In this review, we will examine the role of DCs in the TME, their contributions to tumor progression, and the therapeutic potential of modulating their function in the context of cancer immunotherapy [7,8].

Results

Research has shown that the state of dendritic cells in the tumor microenvironment (TME) plays a critical role in determining the overall immune response against cancer. DCs in the TME often display dysfunctional characteristics, including reduced antigen presentation, impaired T cell activation, and an inability to effectively stimulate antitumor immunity. In contrast to their normal function, where they activate naïve T cells to mount an immune response, DCs in tumors frequently adopt a tolerogenic phenotype, which promotes immune evasion. This phenomenon is often triggered by tumor-derived factors, such as soluble mediators (e.g., TGF-β), metabolic changes, and exosomes that directly influence DC maturation and function. Evidence from several preclinical and clinical studies has shown that DCs can become functionally compromised in the TME, leading to the induction of immunosuppressive mechanisms. For example, IL-10 and TGF-β are cytokines commonly found in the TME that contribute to the inhibition of DC function and the promotion of T regulatory cells (Tregs), which suppress effector T cell activity. In addition to cytokine-driven mechanisms, tumors can alter the metabolic environment, leading to oxidative stress and nutrient deprivation, further impairing DCs’ ability to activate T cells effectively. On the positive side, strategies aimed at enhancing DC function in the TME have shown promise in preclinical models. Approaches such as DC vaccination, ex vivo DC maturation, and targeted delivery of tumor antigens to DCs have demonstrated the potential to overcome DC dysfunction and stimulate potent antitumor responses. Clinical trials investigating the use of DC-based vaccines have reported encouraging results, although challenges remain regarding the optimal methods for DC activation and tumor antigen targeting.

Discussion

Dendritic cells (DCs) are central to both the induction and regulation of immune responses, but their function within the tumor microenvironment (TME) is often subverted by tumor cells. This immunosuppressive shift is characterized by the impairment of antigen-presenting capabilities and the induction of tolerogenic signals that contribute to immune evasion. Several mechanisms contribute to this dysfunctional state of DCs in tumors, including exposure to tumor-derived cytokines (e.g., IL-10, TGF-β), altered metabolic conditions, and the presence of immunosuppressive cells such as T regulatory cells (Tregs). Together, these factors alter the phenotype of DCs, leading to the induction of an immune-suppressive microenvironment that supports tumor growth. Targeting DCs within the TME has emerged as a promising strategy for improving cancer immunotherapy outcomes. There are several approaches under investigation to reverse DC dysfunction, including the use of DC vaccines, which aim to enhance the capacity of DCs to present tumor-associated antigens and stimulate antitumor T cell responses. Another promising strategy involves the use of immune checkpoint inhibitors that target inhibitory receptors on DCs, such as PD-L1, to restore their antigen-presenting function and reinvigorate T cell responses. Despite these advances, several challenges remain. One of the major obstacles is the heterogeneity of DCs within the TME, which may require tailored therapeutic strategies. Additionally, the complex interplay between tumor cells, immune cells, and the TME must be better understood to identify the most effective ways to modulate DC function. Nevertheless, the potential of DC-based immunotherapy to augment current cancer treatments, such as immune checkpoint inhibitors and adoptive T cell therapy, offers exciting opportunities for improving cancer patient outcomes.

Conclusion

Dendritic cells (DCs) are essential mediators of immune responses, and their dysfunction in the tumor microenvironment (TME) plays a pivotal role in tumor immune evasion. While tumors often hijack DCs to create an immunosuppressive environment, strategies to restore or enhance DC function offer promising avenues for immunotherapy. Various therapeutic approaches, such as DC vaccines, immune checkpoint inhibitors, and reprogramming of the TME, are being explored to reinstate the immunostimulatory capabilities of DCs. However, challenges persist in optimizing these therapies, including the need to address DC heterogeneity and the complexity of the TME. Further research is crucial to refine DC-targeted therapies and to better understand the intricate interactions between DCs and other components of the immune system. As immunotherapy continues to evolve, the role of DCs as key regulators in the TME will remain a critical area of focus, with the potential to significantly enhance the efficacy of cancer immunotherapy and improve patient outcomes.

References

1. Hale G, Clark M, Marcus R, Winter G, Dyer M, et al. (1988) Remission induction in non-Hodgkin, lymphoma with reshaped human monoclonal antibody CAMPATH 1-H. Lancet 2: 1394-1399.

Indexed at, Google Scholar, Crossref

2. Schumacher TN, Heemels MT, Neefjes JJ, Kast WM, Melief CJ, et al. (1990) Direct binding of peptide to empty MHC class I molecules on intact cells and in vitro. Cell 62: 563-567.

Indexed at, Google Scholar, Crossref

3. Hale G, Xia MQ, Tighe HP, Dyer M, Waldmann H, et al. (1990) The CAMPATH-1 antigen (CDw52). Tissue Antigens 35: 118-127.

Indexed at, Google Scholar, Crossref

4. Kelly A, Powis SH, Kerr LA, Mockridge I, Elliott T, et al. (1992) Assembly and function of the two ABC transporter proteins encoded in the human major histocompatibility complex. Nature 355: 641-644.

Indexed at, Google Scholar, Crossref

5. Isaacs JD, Watts R, Hazleman BL, Hale G, Keogan MT, et al. (1992) Humanised monoclonal antibody therapy for rheumatoid arthritis.Lancet 340: 748-752.

Indexed at, Google Scholar, Crossref

6. Pachlopnik J, Canioni D, Moshous D, Touzot F, Mahlaoui N, et al. (2011) Clinical similarities and differences of patients with X-linked lymphoproliferative syndrome type 1 (XLP-1/SAP deficiency) versus type 2 (XLP-2/XIAP deficiency). Blood 117: 1522-1529.

Indexed at, Google Scholar, Crossref

7. Henter JI, Horne A, Arico M, Egeler RM, Filipovich AH, et al. (2007) HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 48: 124-131.

Indexed at, Google Scholar, Crossref

8. Zhang K, Jordan MB, Marsh RA, Johnson JA, Kissell D, et al. (2011) Hypomorphic mutations in PRF1, MUNC13-4, and STXBP2 are associated with adult-onset familial HLH. Blood 118: 5794-5798.

Indexed at, Google Scholar, Crossref